300244.SZ
迪安诊断
SZSE · Healthcare · Q 卫生 · CN
CNY 19.82
−4.02%Aug 31, 2026, 14:52 UTC
Di'an Diagnostics launched a new dual-sample tuberculosis molecular detection technology, the Jindi'an Mycobacterium tuberculosis complex nucleic acid detection kit (PCR-fluorescence probe method), developed with Shanghai Infection and Immunity Science and Technology Innovation Center, at the 37th National Academic Conference of the Chinese Anti-Tuberculosis Association on August 30, 2026.
Source:Aug 20, 2026, 10:04 UTC
Di'an Diagnostics announced its H1 2026 results: revenue of 4.773 billion yuan, down 3.30% year-on-year; net profit attributable to shareholders of 232 million yuan, up 2160.87% year-on-year; non-recurring net profit of 239 million yuan, up 2685.60% year-on-year.
Source:Aug 19, 2026, 10:23 UTC
Di'an Diagnostics' controlling shareholder Chen Haibin pledged 16 million shares as collateral to renew an existing loan with China Merchants Securities, extending the pledge from August 18, 2026 to August 18, 2027.
Source: